摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-chloro-7-methyl-1-(1-propylbutyl)-2,3-dihydro-1H-[1,8]naphthyridin-4-one

中文名称
——
中文别名
——
英文名称
5-chloro-7-methyl-1-(1-propylbutyl)-2,3-dihydro-1H-[1,8]naphthyridin-4-one
英文别名
5-Chloro-1-heptan-4-yl-7-methyl-2,3-dihydro-1,8-naphthyridin-4-one
5-chloro-7-methyl-1-(1-propylbutyl)-2,3-dihydro-1H-[1,8]naphthyridin-4-one化学式
CAS
——
化学式
C16H23ClN2O
mdl
——
分子量
294.824
InChiKey
BANAHPVPHQBBIE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    20
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    33.2
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    2,4-二氯-6-甲基吡啶-3-甲酸乙酯 在 lithium aluminium tetrahydride 、 四丙基高钌酸铵草酰氯 、 4 A molecular sieve 、 二甲基亚砜N-甲基吗啉氧化物三乙胺 作用下, 以 四氢呋喃乙醇二氯甲烷 为溶剂, 反应 25.5h, 生成 5-chloro-7-methyl-1-(1-propylbutyl)-2,3-dihydro-1H-[1,8]naphthyridin-4-one
    参考文献:
    名称:
    Potent, Orally Active Corticotropin-Releasing Factor Receptor-1 Antagonists Containing a Tricyclic Pyrrolopyridine or Pyrazolopyridine Core
    摘要:
    Two new classes of tricyclic-based corticotropin-releasing factor (CRF1) receptor-1 antagonists were designed by constraining known 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine ligands. Pyrrole- and pyrazole-based molecules 19g and 22a, respectively, were discovered that potently bind the recombinant CRF1 receptor (K-i = 3.5, 2.9 nM) and inhibit adrenocorticotropic hormone (ACTH) release from rat pituitary cell culture (IC50 = 14, 6.8 nM). These compounds show good oral bioavailabity (F = 24%, 7.0%) and serum half-lives in rats (t(1/2) = 6.3, 12 h) and penetrate the rat brain ([brain]/[plasma] = 0.27, 0.52) but tend toward large volumes of distribution (V-D = 38, 44 L kg(-1)) and rapid clearances (CL = 70, 43 mL min(-1) kg(-1)). When given orally, both the pyrazole and the pyrrole leads dose-dependently inhibit stress-induced ACTH release in vivo. ACTH reductions of 84-86% were observed for 30 mg kg(-1) doses.
    DOI:
    10.1021/jm050070m
点击查看最新优质反应信息